Literature DB >> 31557636

Increased type 2 inflammation post rhinovirus infection in patients with moderate asthma.

Thomas Southworth1, Caroline Pattwell2, Naimat Khan2, Sarah F Mowbray3, Robert M Strieter3, Veit J Erpenbeck4, Dave Singh5.   

Abstract

Rhinovirus (RV) infections are a major cause of exacerbations in patients with asthma. Experimental RV challenges can provide insight into the pathophysiology of viral exacerbations. Previous reports, investigating mild or moderate asthma patients, have shown an upregulation in type 2 inflammation post RV infection, however, studies specifically involving asthma patients taking inhaled corticosteroids have concentrated on symptoms and lung function, rather than the inflammatory response. Eleven moderate asthma patients were inoculated with RV. Cold symptoms and asthma control were assessed at baseline and post infection. Nasal epithelial lining fluid and bronchial alveolar lavage (BAL) fluid were collected at baseline and 4 days post infection for assessment of inflammatory proteins. Patients suffered increased cold symptoms and decreased asthma control within 7 days of infection. Antiviral mechanisms were induced following inoculation, with increases in interferon -α, β, γ and λ, as well as CXCL10 and CXCL11. Type 2 inflammatory cytokines were also significantly elevated post RV infection in both nasal and bronchial samples. In BAL, epithelial derived IL-25 and IL-33 levels strongly correlated with Th2 cytokines, IL-4, IL-5 and IL-13. We show how experimental rhinovirus challenge regulates lung and nasal biomarkers in asthma patients taking inhaled corticosteroids. These biomarkers could be used to evaluate the effects of novel drugs for asthma.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asthma; IL-25; IL-33; Inhaled corticosteroid; Rhinovirus; Type 2 inflammation

Mesh:

Substances:

Year:  2019        PMID: 31557636     DOI: 10.1016/j.cyto.2019.154857

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  8 in total

1.  TLR3/TAK1 signalling regulates rhinovirus-induced interleukin-33 in bronchial smooth muscle cells.

Authors:  Sangeetha Ramu; Jenny Calvén; Charalambos Michaeloudes; Mandy Menzel; Hamid Akbarshahi; Kian Fan Chung; Lena Uller
Journal:  ERJ Open Res       Date:  2020-10-05

2.  Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective.

Authors:  David M G Halpin; Dave Singh; Ruth M Hadfield
Journal:  Eur Respir J       Date:  2020-05-07       Impact factor: 16.671

3.  Identification of Key Signaling Pathways and Genes in Eosinophilic Asthma and Neutrophilic Asthma by Weighted Gene Co-Expression Network Analysis.

Authors:  Gongqi Chen; Dian Chen; Yuchen Feng; Wenliang Wu; Jiali Gao; Chenli Chang; Shengchong Chen; Guohua Zhen
Journal:  Front Mol Biosci       Date:  2022-02-02

4.  Type I conventional dendritic cells relate to disease severity in virus-induced asthma exacerbations.

Authors:  Aoife Cameron; Jaideep Dhariwal; Nadine Upton; Ismael Ranz Jimenez; Malte Paulsen; Ernie Wong; Maria-Belen Trujillo-Torralbo; Ajerico Del Rosario; David J Jackson; Michael R Edwards; Sebastian L Johnston; Ross P Walton
Journal:  Clin Exp Allergy       Date:  2022-03-03       Impact factor: 5.401

5.  Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases.

Authors:  Sulagna Bhattacharya; Sakshi Agarwal; Nishith M Shrimali; Prasenjit Guchhait
Journal:  Mol Aspects Med       Date:  2021-07-19

6.  Rhinovirus Induces Basolateral Release of IL-17C in Highly Differentiated Airway Epithelial Cells.

Authors:  Kyla C Jamieson; Shahina Wiehler; Aubrey N Michi; David Proud
Journal:  Front Cell Infect Microbiol       Date:  2020-03-13       Impact factor: 5.293

7.  Impact of Coronavirus Disease 2019 on the Pediatric Population with Aerodigestive Disease.

Authors:  Beate Beinvogl; Alexandra Cohen; Courtney DiFilippo; Madeline Kane; Samuel Nurko; Rachel Rosen
Journal:  J Pediatr       Date:  2021-12-20       Impact factor: 4.406

Review 8.  Use of corticosteroids in asthma and COPD patients with or without COVID-19.

Authors:  Syed Shahzad Hasan; Toby Capstick; Syed Tabish Razi Zaidi; Chia Siang Kow; Hamid A Merchant
Journal:  Respir Med       Date:  2020-05-26       Impact factor: 4.582

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.